Ainos (AIMD) announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology across high-risk hospital environments. The collaboration aims to expand Ainos’ Smell AI platform from industrial and environmental safety into healthcare infrastructure. The initial deployment, beginning in April 2026, focuses on environmental monitoring and safety across four critical hospital areas.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIMD:
- Ainos reports FY25 revenue $124,157 vs. $20,729 last year
- Ainos CFO says maintained ‘disciplined financial approach’ in FY25
- Ainos says WSJ highlights emerging ‘Smell AI’ in article
- Ainos announces continued validation testing of AI Nose platform
- Ainos CEO says AI Nose platform transitioning into industrial deployment